Aprepitant is effective in the treatment of severe itching caused by biological agents

Aprepitant is effective for the treatment of severe itching caused by biological agents. Itching is a common side effect of anti-EGFR antibody treatment and tyrosine kinase inhibitor treatment. Daniele Santini and others designed a single-center cohort study to evaluate the therapeutic effect of the neuropeptide receptor inhibitor aprepitant on severe itching caused by biological agents. This research was published in the latest online journal of Lancet Oncol in September. This study is a single-center, prospective cohort study. The researchers continuously included 45 outpatients with metastatic solid tumors treated with biological agents. The included subjects were all treated at the Campus Bio-Medico Hospital of Rome in Rome, Italy. The study period was from September 2010 to November 2011. The researchers divided the subjects into two groups: the refractory group or the initial group. The patients in the refractory group received standard treatment for repeated itching, and the patients in the initial group had not previously received treatment for itching. After at least one week of systemic standard treatment, patients in the refractory group received aprepitant at a dose of 125 mg on the first day and 80 mg on the third and fifth days. In the initial group, the patients received the same treatment plan as the refractory group, and the time to receive the treatment was when the first severe itching reaction occurred. The degree of itching was assessed by visual analogue scale (VAS). The primary endpoint of the study was a change in the average VAS score. This study is registered with ClinicalTrials.gov. In the refractory group, the baseline score for VAS was 8.00, and the score after one week of aprepitant treatment was 1.00, suggesting that aprepitant can significantly relieve pruritus symptoms. In the initial group, similar conclusions can be drawn, with a baseline score of 8.00 for VAS and a score of 0.00 after one week of aprepitant treatment. 91% of patients responded to aprepitant treatment (50% less itching) %), Only 13% of patients experienced recurrence of itching. No side effects related to aprepitant treatment were observed in the study. Aprepitant can reduce severe itching caused by biological agents. The drug is an old drug that has been widely used in clinics, so it is easy to add to the treatment plan. The authors point out that as far as they know, there are no other trials to study the effect of aprepitant on itching, but our findings require further verification in phase 2 and phase 3 clinical studies. (

Our outdoor hammock is with its global pioneering design, breaking through convention, utilizing textilene boldly, Sevenze`s garden hammock receives rich reputation. Meanwhile, hard work on hammock stand brings its gorgeous appearance and outstanding quality. Each hammock set, through strict safety test before reaching customer,is safe, reliable, and permanently guaranteed.Hammock

Hammock Bed

Hammock Bed,Indoor Hammock,Chair Hammock,Camping Hammock

SEVENZE INDUSTRAL CO.,LIMITED , http://www.sevenze.com

Posted on